- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Disease staging of Alzheimer’s disease using a CSF-based biomarker model ; volume:4 ; number:5 ; day:21 ; month:3 ; year:2024 ; pages:694-708 ; date:5.2024
Nature aging ; 4, Heft 5 (21.3.2024), 694-708, 5.2024
- Urheber
-
Salvadó, Gemma
Horie, Kanta
Barthélemy, Nicolas R.
Vogel, Jacob W.
Pichet Binette, Alexa
Chen, Charles D.
Aschenbrenner, Andrew J.
Gordon, Brian A.
Benzinger, Tammie L. S.
Holtzman, David M.
Morris, John C.
Palmqvist, Sebastian
Stomrud, Erik
Janelidze, Shorena
Ossenkoppele, Rik
Schindler, Suzanne E.
Bateman, Randall J.
Hansson, Oskar
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s43587-024-00599-y
- URN
-
urn:nbn:de:101:1-2407311016175.716630805056
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Salvadó, Gemma
- Horie, Kanta
- Barthélemy, Nicolas R.
- Vogel, Jacob W.
- Pichet Binette, Alexa
- Chen, Charles D.
- Aschenbrenner, Andrew J.
- Gordon, Brian A.
- Benzinger, Tammie L. S.
- Holtzman, David M.
- Morris, John C.
- Palmqvist, Sebastian
- Stomrud, Erik
- Janelidze, Shorena
- Ossenkoppele, Rik
- Schindler, Suzanne E.
- Bateman, Randall J.
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fluid biomarkers in Alzheimer’s disease – current concepts
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Blood‐based biomarkers for Alzheimer's disease
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume